PUMA BIOTECHNOLOGY INC (PBYI)
US74587V1070 - Common Stock
PBYI gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 588 industry peers in the Biotechnology industry. While PBYI is still in line with the averages on profitability rating, there are concerns on its financial health. PBYI is valued correctly, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year PBYI was profitable.
In the past year PBYI had a positive cash flow from operations.
In the past 5 years PBYI reported 4 times negative net income.
Of the past 5 years PBYI 4 years had a positive operating cash flow.
1.2 Ratios
PBYI has a Return On Assets of 9.37%. This is amongst the best in the industry. PBYI outperforms 97.26% of its industry peers.
PBYI has a better Return On Equity (40.41%) than 99.14% of its industry peers.
PBYI's Return On Invested Capital of 20.05% is amongst the best of the industry. PBYI outperforms 99.14% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for PBYI is below the industry average of 13.60%.
The last Return On Invested Capital (20.05%) for PBYI is above the 3 year average (11.31%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.37% | ||
| ROE | 40.41% | ||
| ROIC | 20.05% |
ROA(3y)-1.16%
ROA(5y)-12.05%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)11.31%
ROIC(5y)N/A
1.3 Margins
With an excellent Profit Margin value of 9.17%, PBYI belongs to the best of the industry, outperforming 96.06% of the companies in the same industry.
PBYI's Operating Margin of 14.12% is amongst the best of the industry. PBYI outperforms 96.23% of its industry peers.
The Gross Margin of PBYI (73.40%) is better than 84.76% of its industry peers.
PBYI's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 14.12% | ||
| PM (TTM) | 9.17% | ||
| GM | 73.4% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.82%
GM growth 5Y-3.17%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), PBYI is creating value.
Compared to 1 year ago, PBYI has more shares outstanding
The number of shares outstanding for PBYI has been increased compared to 5 years ago.
The debt/assets ratio for PBYI has been reduced compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -5.58, we must say that PBYI is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of PBYI (-5.58) is worse than 64.55% of its industry peers.
The Debt to FCF ratio of PBYI is 6.94, which is on the high side as it means it would take PBYI, 6.94 years of fcf income to pay off all of its debts.
PBYI has a Debt to FCF ratio of 6.94. This is amongst the best in the industry. PBYI outperforms 94.52% of its industry peers.
PBYI has a Debt/Equity ratio of 1.23. This is a high value indicating a heavy dependency on external financing.
Looking at the Debt to Equity ratio, with a value of 1.23, PBYI is doing worse than 79.11% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.23 | ||
| Debt/FCF | 6.94 | ||
| Altman-Z | -5.58 |
ROIC/WACC2.15
WACC9.32%
2.3 Liquidity
A Current Ratio of 1.57 indicates that PBYI should not have too much problems paying its short term obligations.
With a Current ratio value of 1.57, PBYI is not doing good in the industry: 82.36% of the companies in the same industry are doing better.
A Quick Ratio of 1.50 indicates that PBYI should not have too much problems paying its short term obligations.
PBYI's Quick ratio of 1.50 is on the low side compared to the rest of the industry. PBYI is outperformed by 81.85% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.57 | ||
| Quick Ratio | 1.5 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 3314649325744685056.00% over the past year.
Looking at the last year, PBYI shows a small growth in Revenue. The Revenue has grown by 3.34% in the last year.
The Revenue has been decreasing by -1.26% on average over the past years.
EPS 1Y (TTM)3314649325744685000%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q316.67%
Revenue 1Y (TTM)3.34%
Revenue growth 3Y1.54%
Revenue growth 5Y-1.26%
Revenue growth Q2Q9.89%
3.2 Future
PBYI is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -19.56% yearly.
PBYI is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 1.49% yearly.
EPS Next Y-42.35%
EPS Next 2Y-38.78%
EPS Next 3Y-49.91%
EPS Next 5Y-19.56%
Revenue Next Year-7.77%
Revenue Next 2Y-4.45%
Revenue Next 3Y-3.06%
Revenue Next 5Y1.49%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 10.91, the valuation of PBYI can be described as very reasonable.
Based on the Price/Earnings ratio, PBYI is valued cheaply inside the industry as 98.46% of the companies are valued more expensively.
When comparing the Price/Earnings ratio of PBYI to the average of the S&P500 Index (24.92), we can say PBYI is valued rather cheaply.
The Price/Forward Earnings ratio is 18.93, which indicates a rather expensive current valuation of PBYI.
Based on the Price/Forward Earnings ratio, PBYI is valued cheaper than 97.09% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 21.49. PBYI is around the same levels.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.91 | ||
| Fwd PE | 18.93 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, PBYI is valued cheaply inside the industry as 98.63% of the companies are valued more expensively.
97.43% of the companies in the same industry are more expensive than PBYI, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 16.84 | ||
| EV/EBITDA | 5.08 |
4.3 Compensation for Growth
PBYI has a very decent profitability rating, which may justify a higher PE ratio.
PBYI's earnings are expected to decrease with -49.91% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-38.78%
EPS Next 3Y-49.91%
5. Dividend
5.1 Amount
No dividends for PBYI!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
PUMA BIOTECHNOLOGY INC
NASDAQ:PBYI (4/26/2024, 7:09:01 PM)
After market: 5.02 0 (0%)5.02
+0.14 (+2.87%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap242.01M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.91 | ||
| Fwd PE | 18.93 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.37% | ||
| ROE | 40.41% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 14.12% | ||
| PM (TTM) | 9.17% | ||
| GM | 73.4% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover1.02
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.23 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.57 | ||
| Quick Ratio | 1.5 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)3314649325744685000%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-42.35%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)3.34%
Revenue growth 3Y1.54%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y